Acamprosate

Alcohol Use Disorder Market to Witness Positive Growth at a CAGR of 8.8% by 2032 | DelveInsight

Retrieved on: 
Wednesday, September 28, 2022
Memantine, New, Social stigma, GHB, Perspiration, Compliance, ASP, Topiramate, Lists of diseases, Patient, Disulfiram, United Kingdom, Benzodiazepine, Astellas Pharma, National Institute, AUD, Psychiatric and mental health nursing, Prevalence, GABAB, Knowledge, Biomarker, Growth, Acamprosate, Alcoholism, Attention, Otsuka Pharmaceutical, Diagnostic and Statistical Manual of Mental Disorders, Drinking, ALKS, Health care, SMO, Gabapentin, Seizure, Corcept Therapeutics, Diagnosis, Hope, Population, Baclofen, Sodium oxybate, DSM, CORT, DSM-IV, LAS, VIVITROL, Mood Swings, National Institute on Alcohol Abuse and Alcoholism, Aripiprazole, Therapy, ALKS 3831, US FDA, DSM-V, Varenicline, Novo Nordisk, Pharmaceutical industry, Lithium, Alkermes, Ondansetron

LAS VEGAS, Sept. 28, 2022 /PRNewswire/ --DelveInsight's Alcohol Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, alcohol use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • Leading alcohol use disordercompanies such as Alkermes, Lundbeck, Otsuka Pharmaceuticals, Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, and others are developing novel alcohol use disorder drugs that can be available in the alcohol use disorder market in the upcoming years.
  • DelveInsight estimates that there were approximately 25 million 12-month diagnosed prevalent cases of alcohol use disorder in the 7MM in 2021.
  • TOPAMAX (topiramate) is even recommended for alcohol use disorder treatment by the National Institute on Alcohol Abuse and Alcoholism.
  • Moreover, because of the change in alcohol use disorder diagnostic criteria from DSM-IV to DSM-V, country-specific epidemiologic data on diagnosis, severity, and treatment are scarce and thus limiting the alcohol use disorder market growth.

U.S. Substance Abuse Treatment Market Research Report 2022: Surging Rate of Drug Addiction And the Growing Prevalence of Alcohol and Smoking Among U.S. Teenagers Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 2, 2022
General Health, Pharmaceutical, Health, Other Health, Market share analysis, Acquisition, R, Investment, State, Value, Decision-making, Smoking, Cognitive behavioral treatment of eating disorders, Use, Cocaine, North American gambling treatment centers, Passages Malibu, Pharmacy, Bupropion, Research, Hospital, Strategic management, Group, Methadone, Customer support, USD, Naltrexone, CAGR, Certification, Substance Abuse, Patient, Awareness, Nicotine, Market share, Discrimination against drug addicts, Prevalence, Drug, Growth, Rate, Business Growth Fund, California Substance Abuse Treatment Facility and State Prison, Corcoran, Retail, Varenicline, Buprenorphine, Acamprosate, Disulfiram

This research report categorizes the Substance Abuse Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Substance Abuse Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Substance Abuse Type, the market was studied across Alcohol Addiction, Cocaine, Marijuana, and Nicotine Addiction.
  • Based on Treatment Option, the market was studied across Group Counseling, In-patient Treatment, Individualized Drug Counseling, Long-Term Residential Treatment, Outpatient Treatment Programs, and Short-Term Residential Treatment.
  • Based on State, the market was studied across California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio, Pennsylvania, Tennessee, Texas, and Wisconsin.
  • Surging Rate of Drug Addiction And the Growing Prevalence of Alcohol and Smoking Among U.S. Teenagers
    Rising Patient Awareness through Significant Drug Awareness Campaigns and Prevention Programs in the U.S.

Oar Health Study Reveals Nearly a Third of Americans Want to Change Their Relationship with Alcohol But Don't Know How

Retrieved on: 
Monday, March 28, 2022
Opioid overdose, Family, Atorvastatin, NYU, Telehealth, IAC, Alcoholics Anonymous, Gaps, Sertraline, Sex, Friends, Privacy, Research, Disulfiram, Mental health service, Topical steroid withdrawal, Sleep, Confidentiality, Naloxone, CEO, Sildenafil, Alcoholism, Weight loss, Substance Abuse, Substance Abuse and Mental Health Services Administration, Goal, Time, Drinking, Fluoxetine, Acamprosate, Awareness, Depression, FDA, Patient, Naltrexone, Pharmaceutical industry, NewCo

It is a longstanding public health 'fail' that these medications are relatively unknown, while Viagra and Prozac are household names."

Key Points: 
  • It is a longstanding public health 'fail' that these medications are relatively unknown, while Viagra and Prozac are household names."
  • Naloxone (Narcan), used to treat opioid overdoses, was familiar to 40% of respondents who want to drink less or quit.
  • "Contrary to conventional wisdom, people who are struggling with alcohol misuse are not universally in denial about the need to change their relationship with alcohol," said Jonathan Hunt-Glassman, Founder and CEO of Oar Health.
  • Oar Health is based in Brooklyn, NY and is a part of Newco, IAC's incubation platform.